Genome-Wide Scan of Brothers: Replication and Fine Mapping of Prostate Cancer Susceptibility and Aggressiveness Loci

Prostate

Volumn 57, Issue 4, 2003, Pages 298-308

  Witte, John S ^a,h   Suarez, Brian K ^b   Thiel, Bonnie ^c   Lin, Jennifer ^d   Yu, Adong ^e   Banerjee, Tarit K ^e   Burmester, James K ^e   Casey, Graham ^f   Catalona, William J ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MARSHFIELD CLINIC   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Affected siblings; Carcinogenesis; Linkage; Prostate cancer genetics; Urology

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMOSOME 10Q; CHROMOSOME 11Q; CHROMOSOME 16P; CHROMOSOME 16Q; CHROMOSOME 18P; CHROMOSOME 19Q; CHROMOSOME 2Q; CHROMOSOME 5P; CHROMOSOME 5Q; CHROMOSOME 7Q; DISEASE SEVERITY; GENE LOCUS; GENE MAPPING; GENE REPLICATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM; SIBLING; UNITED STATES; UROLOGY;

AGED; CHROMOSOME MAPPING; DNA, NEOPLASM; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GENOTYPE; HUMANS; LINKAGE (GENETICS); MALE; MICROSATELLITE REPEATS; MIDDLE AGED; PROSTATIC NEOPLASMS; SIBLINGS;

EID: 0345374576     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10304     Document Type: Article

References (66)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer Statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-864.
3. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996;274:1371-1374.
4. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G, Latil A, Millasseau P, Mellah I, Cohen N, Blanche H, Bellane-Chantelot C, Demenais F, Teillac P, Le Duc A, de Petriconi R, Hautmann R, Chumakov I, Bachner L, Maitland NJ, Lidereau R, Vogel W, Fournier G, Mangin P, Cohen D, Cussenot O. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998;62:1416-1424.
5. Gibbs M, Stanford JL, McIndoe RA, Jarvik GP, Kolb S, Goode EL, Chakrabarti L, Schuster EF, Buckley VA, Miller EL, Brandzel S, Li S, Hood L, Ostrander EA. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 1999;64:776-787.
6. Xu J, Zheng SL, Hawkins GA, Faith DA, Kelly B, Isaacs SD, Wiley KE, Chang B, Ewing CM, Bujnovszky P, Carpten JD, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB. Linkage and association studies of prostate cancer susceptibility: Evidence for linkage at 8p22-23. Am J Hum Genet 2001;69:341-350.
7. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright LA. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001;27:172-180.
8. Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ, Cunningham JM, Thibodeau SN, Schaid DJ. Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 2000;67:82-91.
9. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Trent J, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998;20:175-179.
10. Carpten JD, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein M, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikainen M, Schleutker J, Klinger K, Connors T, Xiang Y, Wang Z, De Marzo A, Papadopoulos N, Kallioniemi OP, Burk R, Meyers D, Gronberg H, Meltzer P, Silverman R, Bailey-Wilson JE, Walsh PC, Isaacs WB, Trent JM. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002;30:181-184.
11. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A, Ewing CM, Faith DA, Johnson JR, Suzuki H, Bujnovszky P, Wiley KE, DeMarzo AM, Bova GS, Chang B, Hall MC, McCullough DL, Partin AW, Kassabian VS, Carpten JD, Bailey-Wilson JE, Trent JM, Ohar J, Bleecker ER, Walsh PC, Isaacs WB, Meyers DA. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002;32:321-325.
12. Ostrander EA, Stanford JL. Genetics of prostate cancer: Too many loci, too few genes. Am J Hum Genet 2000;67:1367-1375.
13. Neville PJ, Casey G, Witte JS. Hereditary prostate cancer and genetic Risk. In: Klein Eric, editor. Management of prostate cancer, 2nd edn. New Jersey: Humana Press, Inc., 2003.
14. Suarez BK, Lin J, Burmester JK, Broman K, Weber JL, Banerjee TK, Goddard KA, Witte JS, Elston RC, Catalona WJ. A genome screen of multiplex sibships with prostate cancer. Am J Hum Genet 2000a;66:933-944.
15. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Issacs WB. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci 1990;87:8751-8755.
16. Elo JP, Harkonen P, Kyllonen AP, Lukkarinen O, Poutanen M, Vihko R, Vihko P. Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res 1997;57:3356-3359.
17. Latil A, Cussenof O, Fournier G, Driouch K, Libereau R. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: Identification of three independent regions. Cancer Res 1997;57:1058-1062.
18. Elo JP, Harkonen P, Kyllonen AP, Lukkarinen O, Vihko P. Three independently deleted regions at chromosome arm 16q in human prostate cancer: Allelic loss at 16q24.1-q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumor, and poor prognosis for the patient. Br J Cancer 1999;79:156-160.
19. Paris PL, Witte JS, Kupelian PA, Levin H, Klein EA, Catalona W, Casey G. Identification and fine mapping of a commonly deleted prostate cancer suppressor gene locus on chromosome 16q23.2 that corresponds to a prostate cancer susceptibility locus. Cancer Res 2000;60:3645-3649.
20. Suarez BK, Lin J, Witte JS, Conti DV, Resnick MI, Klein EA, Burmester JK, Vaske DA, Banerjee TK, Catalona WJ. Replication linkage study for prostate cancer susceptibility genes. Prostate 2000b;45:106-114.
21. Witte JS, Goddard KA, Conti DV, Elston RC, Lin J, Suarez BK, Broman KW, Burmester JK, Weber JL, Catalona WJ. Genome-wide scan for prostate cancer-aggressiveness loci. Am J Hum Genet 2000;67:92-99.
22. Gleason DF. Histologic grading of prostate cancer - A perspective. Hum Pathol 1992;23:273-279.
23. Neville PJ, Conti DV, Paris PL, Levin H, Catalona WJ, Suarez BK, Witte JS, Casey G. Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies. Neoplasia 2002;4:424-431.
24. Neville PJ, Conti DV, Krumroy LM, Catalona WJ, Suarez BK, Witte JS, Casey G. Prostate cancer aggressiveness locus on chromosome segment 19q12-q13.1 identified by linkage and allelic imbalance studies. Genes Chromosomes Cancer 2003;36:332-339.
25. Paiss T, Worner S, Kurtz F, Haeussler J, Hautmann RE, Gschwend JE, Herkommer K, Vogel W. Linkage of aggressive prostate cancer to chromosome 7q31-33 in German prostate cancer families. Eur J Hum Genet 2003;11:17-22.
26. Slager SL, Schaid DJ, Cunningham JM, McDonnell SK, Marks AF, Peterson BJ, Hebbring SJ, Anderson S, French AJ, Thibodeau SN. Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. Am J Hum Genet 2003;72:759-762.
27. Goddard KA, Witte JS, Suarez BK, Catalona WJ, Olson JM. Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4. Am J Hum Genet 2001;68:1197-1206.
28. Yuan B, Vaske D, Weber JL, Beck J, Sheffield VC. Improved set of short-tandem-repeat polymorphisms for screening the human genome. Am J Hum Genet 1997;60:459-460.
29. Broman KW, Murray JC, Sheffield VC, White RL, Weber JL. Comprehensive human genetic maps: Individual and sex-specific variation in recombination. Am J Hum Genet 1998;63:1563-1564.
30. S.A.G.E. Statistical Analysis for Genetic Epidemiology, Release 4.3. Computer program available from the Department of Epidemiology and Biostatistics, Rammelkamp Center for Education and Research, MetroHealth Campus, Case Western Reserve University, Cleveland, 2003.
31. Elston RC, Buxbaum S, Jacobs KB, Olson JM. Haseman and Elston revisited. Genet Epidemiol 2000;19:1-17.
32. Haseman JK, Elston RC. The investigation of linkage between a quantitative trait and a marker locus. Behav Genet 1972;2:3-19.
33. Terwilliger JD, Shannon WD, Lathrop GM, Nolan JP, Goldin LR, Chase GA, Weeks DE. True and false positive peaks in genome-wide scans: Applications of length-based sampling to linkage mapping. Am J Hum Genet 1997;61:430-438.
34. Cher ML, Ito T, Weidner N, Carroll PR, Jensen RH. Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization. J Urol 1995;153:249-254.
35. Suzuki H, Komiya A, Emi M, Kuramochi H, Shiraishi R, Yatani R. Shimazaki J. Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosomes Cancer 1996;17:225-233.
36. Godfrey TE, Cher ML, Chhabra V, Jensen RH. Allelic imbalance mapping of chromosome 16 shows two regions of common deletion in prostate adenocarcinoma. Cancer Genet Cytogenet 1997;98:36-42.
37. Osman I, Scher H, Dalbagni G, Reuter V, Zhang Z. Cordon-Cardo C. Chromosome 16 in primary prostate cancer: A microsatellite analysis. Int J Cancer 1997;71:580-584.
38. Strup SE, Pozzatti RO, Florence CD, Emmert-Buck MR, Duray PH, Liotta LA, Bostwick DG, Linehan WM, Vocke CD. Chromosome 16 allelic loss analysis of a large set of microdissected prostate carcinomas. J Urol 1999;162:590-594.
39. Mangelsdorf M, Ried K, Woollatt E, Dayan S, Eyre H, Finnis M, Hobson L, Nancarrow J, Venter D, Baker E, Richards RI. Chromosomal fragile site FRA16D and DNA instability in cancer. Cancer Res 2000;60:1683-1689.
40. Paige AJ, Taylor KJ, Stewart A, Sgouros JG, Gabra H, Sellar GC, Smyth JF, Porteous DJ, Watson JE. A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res 2001;60:1690-1696.
41. Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Bents LA, Chen T, Schrock E, Ried T, Kuel WM. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998;91:4457-4463.
42. Bednarek AK, Keck-Waggoner CL, Daniel RL, Laflin KJ, Bergsagel PL, Kiguchi K, Brenner AJ, Aldaz CM. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 2001;61:8068-8073.
43. Chang NS, Pratt N, Heath J, Schultz L, Sleve D, Carey GB, Zevotek N. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem 2001;276:3361-3370.
44. Zenklusen JC, Thompson JC, Troncoso P, Kagan J, Conti CL. Loss of heterozygosity in human primary prostate carcinomas: A possible tumor suppressor gene at 7q31.1. Cancer Res 1994;54:6370-6373.
45. Latil A, Cussenot O, Fournier G, Baron JC, Lidereau R. Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer. Clin Cancer Res 1995;1:1385-1389.
46. Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins RB. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res 1994;54:3574-3579.
47. Oakahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, Lieber MM, Thibodeau SN, Jenkins RB. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 1995;55:4113-4119.
48. Jenkins R, Takahashi S, DeLacey K, Bergstralh E, Lieber M. Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer. Genes Chromosomes Cancer 1998;21:131-143.
49. Adams JC, Seed B, Lawler J. Muskelin, a novel intracellular mediator of cell adhesive and cytoskeletal responses to thrombospondin-1. Embo J 1998;17:4964-4974.
50. Adams JC, Kelso R, Cooley L. The kelch repeat superfamily of proteins: Propellers of cell function. Trends Cell Biol 2000;10:17-24.
51. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-1584.
52. Bertin N, Clezardin P, Kubiak R, Frappart L. Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: Correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. Cancer Res 1997;57:396-399.
53. Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001;49:293-305.
54. Mehta R, Kyshtoobayeva A, Kurosaki T, Small EJ, Kim H, Stroup R, McLaren CE, Li KT, Fruehauf JP. Independent association of angiogenesis index with outcome in prostate cancer. Clin Cancer Res 2001;7:81-88.
55. Kershaw DB, Beck SG, Wharram BL, Wiggins JE, Goyal M, Thomas PE, Wiggins RC. Molecular cloning and characterization of human podocalyxin-like protein. Orthologous relationship to rabbit PCLP1 and rat podocalyxin. J Biol Chem 1997;272:15708-15714.
56. Sassetti C, Tangemann K, Singer MS, Kershaw DB, Rosen SD. Identification of podocalyxin-like protein as a high endothelial venule ligand for L-selectin: Parallels to CD34. J Exp Med 1998;187:1965-1975.
57. Takeda T, Go WY, Orlando RA, Farquhar MG. Expression of podocalyxin inhibits cell-cell adhesion and modifies junctional properties in Madin-Darby canine kidney cells. Mol Biol Cell 2000;11:3219-3232.
58. Teruyama K, Abe M, Nakano T, Takahashi S, Yamada S, Sato Y. Neurophilin-1 is a downstream target of transcription factor Ets-1 in human umbilical vein endothelial cells. FEBS Lett 2001;504:1-4.
59. Guo JK, Menke AL, Gubler MC, Clarke AR, Harrison D, Hammes A, Hastie ND, Schedl A. WT1 is a key regulator of podocyte function: Reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum Mol Genet 2002;11:651-659.
60. Palmer RE, Kotsianti A, Cadman B, Boyd T, Gerald W, Haber DA. WT1 regulates the expression of the major glomerular podocyte membrane protein podocalyxin. Curr Biol 2001;11:1805-1809.
61. Palmer LJ, Jacobs KB, Elston RC. Haseman and Elston revisited: The effects of ascertainment and residual familial correlations on power to detect linkage. Genet Epidemiol 2000;19:456-460.
62. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990;143:742-746.
63. Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM. Molecular biology of prostate cancer progression. Cancer Surv 1995;23:19-32.
64. Hayward SW, Grossfeld GD, Tlsty TD, Cunha GR. Genetic and epigenetic influences in prostatic carcinogenesis. Int J Oncol 1998;113:35-47.
65. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
66. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.